Approaches to optimal dosing of hexamethylene bisacetamide

Barbara A. Conley, Merrill J. Egorin, Victoria Sinibaldi, Gerald Sewack, Curtis Kloc, Lynelle Roberts, Eleanor G. Zuhowski, Alan Forrest, David A. Van Echo

Research output: Contribution to journalArticle

Abstract

HMBA is a potent differentiating agent capable of causing>95% morphological differentiation in cell lines in vitro. The induction of differentiation is dependent on both the concentration of and the duration of exposure to HMBA. However, acute toxicities (neurotoxicity and acidosis) have limited the maximal HMBA css value to ss values have been maintained at 1-2 mm, thrombocytopenia has limited the duration of HMBA infusion to ≤10 days. The present studies were performed to determine whether exposure to HMBA could be individualized and maximized without resulting in intolerable toxicity to patients and to determine which factors would predispose a patient to the development of acute toxicity during treatment with HMBA. For these investigations, patients were given HMBA at a target css using an adaptive-feedback-control method rather than at a set dose. Because HMBA administration produces large anion gaps, a simple maneuver such as alkalinization might enable the escalation of plasma HMBA css values to >2 mm. HMBA was given as a 5-day CI to 14 patients (26 courses) at 2 target HMBA css levels near the maximal tolerated value in the presence or absence of concurrent alkalinization with sodium bicarbonate. Symptomatic acidosis occurred in one patient who did not receive bicarbonate. Neurotoxicity proved to be dose-limiting at the target HMBA css value of 1.5-2.0 mm in the absence of concurrent alkalinization and at a css level of >2 mm, regardless of alkalinization. No neurotoxicity was seen at target HMBA css values of 1.5-2.0 mm in patients who did receive concurrent alkalinization. Alkalinization was not associated with any detectable changes in plasma HMBA metabolites. With the maximal tolerable 5-day HMBA css having thus been defined at 1.5-2.0 mm, we attempted to maximize exposure to HMBA by defining a tolerable duration of infusion. Individualization of the duration of HMBA infusion to a target nadir PLT was performed in patients who had received an initial 5-day CI of HMBA at a css 1.5-2.0 mm along with concurrent alkalinization. The AUC achieved and the thrombocytopenia produced during this first course were used to predict the duration of infusion that each patient would subsequently tolerate (at an HMBA css of 1-2 mm) to achieve a nadir PLT of 75,000-100,000/μl. The observed percentage changes in PLT matched the predicted percentage change in PLT, with the mean error (ME) being -8.9%. For a better determination as to which factors may contribute to neurotoxicity or acidosis in patients receiving HMBA, 98 courses of HMBA given as 5- to 10-day CIs to 56 patients were analyzed (multifactorial logistic regression). An HMBA AUC value of >7.5 mm x day, the use of any concomitant narcotic analgesics, and a mean plasma HMBA level of >1.5 mm or a peak plasma concentration of ≥1.75 mm correlated significantly with grade 3 neurotoxicity (P7.5 mm x day, a mean or peak plasma HMBA level of >1.5 mm, and an age of >70 years correlated with the likelihood of a large anion gap (Pcr value showed any correlation with these toxicities in this patient population. These results imply that HMBA may be given for individualized durations at a css of 1.5 mm in the presence or absence of concomitant alkalinization and that narcotic analgesics should not be given to patients receiving this agent. However, due to the resultant acute neurotoxicity, it is unlikely that AUCs of >7.5 mm x day will be tolerated during simultaneous maintenance of a css value of >1.0 mm.

Original languageEnglish (US)
Pages (from-to)37-45
Number of pages9
JournalCancer Chemotherapy and Pharmacology
Volume31
Issue number1
DOIs
StatePublished - Jan 1992
Externally publishedYes

Fingerprint

hexamethylene bisacetamide
Toxicity
Plasmas
Acidosis
Area Under Curve

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Conley, B. A., Egorin, M. J., Sinibaldi, V., Sewack, G., Kloc, C., Roberts, L., ... Van Echo, D. A. (1992). Approaches to optimal dosing of hexamethylene bisacetamide. Cancer Chemotherapy and Pharmacology, 31(1), 37-45. https://doi.org/10.1007/BF00695992

Approaches to optimal dosing of hexamethylene bisacetamide. / Conley, Barbara A.; Egorin, Merrill J.; Sinibaldi, Victoria; Sewack, Gerald; Kloc, Curtis; Roberts, Lynelle; Zuhowski, Eleanor G.; Forrest, Alan; Van Echo, David A.

In: Cancer Chemotherapy and Pharmacology, Vol. 31, No. 1, 01.1992, p. 37-45.

Research output: Contribution to journalArticle

Conley, BA, Egorin, MJ, Sinibaldi, V, Sewack, G, Kloc, C, Roberts, L, Zuhowski, EG, Forrest, A & Van Echo, DA 1992, 'Approaches to optimal dosing of hexamethylene bisacetamide', Cancer Chemotherapy and Pharmacology, vol. 31, no. 1, pp. 37-45. https://doi.org/10.1007/BF00695992
Conley, Barbara A. ; Egorin, Merrill J. ; Sinibaldi, Victoria ; Sewack, Gerald ; Kloc, Curtis ; Roberts, Lynelle ; Zuhowski, Eleanor G. ; Forrest, Alan ; Van Echo, David A. / Approaches to optimal dosing of hexamethylene bisacetamide. In: Cancer Chemotherapy and Pharmacology. 1992 ; Vol. 31, No. 1. pp. 37-45.
@article{5af14d241da7476cb36f23d7df8cb8ac,
title = "Approaches to optimal dosing of hexamethylene bisacetamide",
abstract = "HMBA is a potent differentiating agent capable of causing>95{\%} morphological differentiation in cell lines in vitro. The induction of differentiation is dependent on both the concentration of and the duration of exposure to HMBA. However, acute toxicities (neurotoxicity and acidosis) have limited the maximal HMBA css value to ss values have been maintained at 1-2 mm, thrombocytopenia has limited the duration of HMBA infusion to ≤10 days. The present studies were performed to determine whether exposure to HMBA could be individualized and maximized without resulting in intolerable toxicity to patients and to determine which factors would predispose a patient to the development of acute toxicity during treatment with HMBA. For these investigations, patients were given HMBA at a target css using an adaptive-feedback-control method rather than at a set dose. Because HMBA administration produces large anion gaps, a simple maneuver such as alkalinization might enable the escalation of plasma HMBA css values to >2 mm. HMBA was given as a 5-day CI to 14 patients (26 courses) at 2 target HMBA css levels near the maximal tolerated value in the presence or absence of concurrent alkalinization with sodium bicarbonate. Symptomatic acidosis occurred in one patient who did not receive bicarbonate. Neurotoxicity proved to be dose-limiting at the target HMBA css value of 1.5-2.0 mm in the absence of concurrent alkalinization and at a css level of >2 mm, regardless of alkalinization. No neurotoxicity was seen at target HMBA css values of 1.5-2.0 mm in patients who did receive concurrent alkalinization. Alkalinization was not associated with any detectable changes in plasma HMBA metabolites. With the maximal tolerable 5-day HMBA css having thus been defined at 1.5-2.0 mm, we attempted to maximize exposure to HMBA by defining a tolerable duration of infusion. Individualization of the duration of HMBA infusion to a target nadir PLT was performed in patients who had received an initial 5-day CI of HMBA at a css 1.5-2.0 mm along with concurrent alkalinization. The AUC achieved and the thrombocytopenia produced during this first course were used to predict the duration of infusion that each patient would subsequently tolerate (at an HMBA css of 1-2 mm) to achieve a nadir PLT of 75,000-100,000/μl. The observed percentage changes in PLT matched the predicted percentage change in PLT, with the mean error (ME) being -8.9{\%}. For a better determination as to which factors may contribute to neurotoxicity or acidosis in patients receiving HMBA, 98 courses of HMBA given as 5- to 10-day CIs to 56 patients were analyzed (multifactorial logistic regression). An HMBA AUC value of >7.5 mm x day, the use of any concomitant narcotic analgesics, and a mean plasma HMBA level of >1.5 mm or a peak plasma concentration of ≥1.75 mm correlated significantly with grade 3 neurotoxicity (P7.5 mm x day, a mean or peak plasma HMBA level of >1.5 mm, and an age of >70 years correlated with the likelihood of a large anion gap (Pcr value showed any correlation with these toxicities in this patient population. These results imply that HMBA may be given for individualized durations at a css of 1.5 mm in the presence or absence of concomitant alkalinization and that narcotic analgesics should not be given to patients receiving this agent. However, due to the resultant acute neurotoxicity, it is unlikely that AUCs of >7.5 mm x day will be tolerated during simultaneous maintenance of a css value of >1.0 mm.",
author = "Conley, {Barbara A.} and Egorin, {Merrill J.} and Victoria Sinibaldi and Gerald Sewack and Curtis Kloc and Lynelle Roberts and Zuhowski, {Eleanor G.} and Alan Forrest and {Van Echo}, {David A.}",
year = "1992",
month = "1",
doi = "10.1007/BF00695992",
language = "English (US)",
volume = "31",
pages = "37--45",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Approaches to optimal dosing of hexamethylene bisacetamide

AU - Conley, Barbara A.

AU - Egorin, Merrill J.

AU - Sinibaldi, Victoria

AU - Sewack, Gerald

AU - Kloc, Curtis

AU - Roberts, Lynelle

AU - Zuhowski, Eleanor G.

AU - Forrest, Alan

AU - Van Echo, David A.

PY - 1992/1

Y1 - 1992/1

N2 - HMBA is a potent differentiating agent capable of causing>95% morphological differentiation in cell lines in vitro. The induction of differentiation is dependent on both the concentration of and the duration of exposure to HMBA. However, acute toxicities (neurotoxicity and acidosis) have limited the maximal HMBA css value to ss values have been maintained at 1-2 mm, thrombocytopenia has limited the duration of HMBA infusion to ≤10 days. The present studies were performed to determine whether exposure to HMBA could be individualized and maximized without resulting in intolerable toxicity to patients and to determine which factors would predispose a patient to the development of acute toxicity during treatment with HMBA. For these investigations, patients were given HMBA at a target css using an adaptive-feedback-control method rather than at a set dose. Because HMBA administration produces large anion gaps, a simple maneuver such as alkalinization might enable the escalation of plasma HMBA css values to >2 mm. HMBA was given as a 5-day CI to 14 patients (26 courses) at 2 target HMBA css levels near the maximal tolerated value in the presence or absence of concurrent alkalinization with sodium bicarbonate. Symptomatic acidosis occurred in one patient who did not receive bicarbonate. Neurotoxicity proved to be dose-limiting at the target HMBA css value of 1.5-2.0 mm in the absence of concurrent alkalinization and at a css level of >2 mm, regardless of alkalinization. No neurotoxicity was seen at target HMBA css values of 1.5-2.0 mm in patients who did receive concurrent alkalinization. Alkalinization was not associated with any detectable changes in plasma HMBA metabolites. With the maximal tolerable 5-day HMBA css having thus been defined at 1.5-2.0 mm, we attempted to maximize exposure to HMBA by defining a tolerable duration of infusion. Individualization of the duration of HMBA infusion to a target nadir PLT was performed in patients who had received an initial 5-day CI of HMBA at a css 1.5-2.0 mm along with concurrent alkalinization. The AUC achieved and the thrombocytopenia produced during this first course were used to predict the duration of infusion that each patient would subsequently tolerate (at an HMBA css of 1-2 mm) to achieve a nadir PLT of 75,000-100,000/μl. The observed percentage changes in PLT matched the predicted percentage change in PLT, with the mean error (ME) being -8.9%. For a better determination as to which factors may contribute to neurotoxicity or acidosis in patients receiving HMBA, 98 courses of HMBA given as 5- to 10-day CIs to 56 patients were analyzed (multifactorial logistic regression). An HMBA AUC value of >7.5 mm x day, the use of any concomitant narcotic analgesics, and a mean plasma HMBA level of >1.5 mm or a peak plasma concentration of ≥1.75 mm correlated significantly with grade 3 neurotoxicity (P7.5 mm x day, a mean or peak plasma HMBA level of >1.5 mm, and an age of >70 years correlated with the likelihood of a large anion gap (Pcr value showed any correlation with these toxicities in this patient population. These results imply that HMBA may be given for individualized durations at a css of 1.5 mm in the presence or absence of concomitant alkalinization and that narcotic analgesics should not be given to patients receiving this agent. However, due to the resultant acute neurotoxicity, it is unlikely that AUCs of >7.5 mm x day will be tolerated during simultaneous maintenance of a css value of >1.0 mm.

AB - HMBA is a potent differentiating agent capable of causing>95% morphological differentiation in cell lines in vitro. The induction of differentiation is dependent on both the concentration of and the duration of exposure to HMBA. However, acute toxicities (neurotoxicity and acidosis) have limited the maximal HMBA css value to ss values have been maintained at 1-2 mm, thrombocytopenia has limited the duration of HMBA infusion to ≤10 days. The present studies were performed to determine whether exposure to HMBA could be individualized and maximized without resulting in intolerable toxicity to patients and to determine which factors would predispose a patient to the development of acute toxicity during treatment with HMBA. For these investigations, patients were given HMBA at a target css using an adaptive-feedback-control method rather than at a set dose. Because HMBA administration produces large anion gaps, a simple maneuver such as alkalinization might enable the escalation of plasma HMBA css values to >2 mm. HMBA was given as a 5-day CI to 14 patients (26 courses) at 2 target HMBA css levels near the maximal tolerated value in the presence or absence of concurrent alkalinization with sodium bicarbonate. Symptomatic acidosis occurred in one patient who did not receive bicarbonate. Neurotoxicity proved to be dose-limiting at the target HMBA css value of 1.5-2.0 mm in the absence of concurrent alkalinization and at a css level of >2 mm, regardless of alkalinization. No neurotoxicity was seen at target HMBA css values of 1.5-2.0 mm in patients who did receive concurrent alkalinization. Alkalinization was not associated with any detectable changes in plasma HMBA metabolites. With the maximal tolerable 5-day HMBA css having thus been defined at 1.5-2.0 mm, we attempted to maximize exposure to HMBA by defining a tolerable duration of infusion. Individualization of the duration of HMBA infusion to a target nadir PLT was performed in patients who had received an initial 5-day CI of HMBA at a css 1.5-2.0 mm along with concurrent alkalinization. The AUC achieved and the thrombocytopenia produced during this first course were used to predict the duration of infusion that each patient would subsequently tolerate (at an HMBA css of 1-2 mm) to achieve a nadir PLT of 75,000-100,000/μl. The observed percentage changes in PLT matched the predicted percentage change in PLT, with the mean error (ME) being -8.9%. For a better determination as to which factors may contribute to neurotoxicity or acidosis in patients receiving HMBA, 98 courses of HMBA given as 5- to 10-day CIs to 56 patients were analyzed (multifactorial logistic regression). An HMBA AUC value of >7.5 mm x day, the use of any concomitant narcotic analgesics, and a mean plasma HMBA level of >1.5 mm or a peak plasma concentration of ≥1.75 mm correlated significantly with grade 3 neurotoxicity (P7.5 mm x day, a mean or peak plasma HMBA level of >1.5 mm, and an age of >70 years correlated with the likelihood of a large anion gap (Pcr value showed any correlation with these toxicities in this patient population. These results imply that HMBA may be given for individualized durations at a css of 1.5 mm in the presence or absence of concomitant alkalinization and that narcotic analgesics should not be given to patients receiving this agent. However, due to the resultant acute neurotoxicity, it is unlikely that AUCs of >7.5 mm x day will be tolerated during simultaneous maintenance of a css value of >1.0 mm.

UR - http://www.scopus.com/inward/record.url?scp=0026451999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026451999&partnerID=8YFLogxK

U2 - 10.1007/BF00695992

DO - 10.1007/BF00695992

M3 - Article

C2 - 1333894

AN - SCOPUS:0026451999

VL - 31

SP - 37

EP - 45

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -